Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 701–800 of 1,000
Nuclear envelope budding inhibition slows down progerin-induced aging process
Wang, X., Ma, L., Lu, D., Gan, Z., Ren, H., Lin, Q., Jia, M., Huang, F., Wang, S., Xu, Z., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321378121 · Cited by 13
Mechanism of dimer selectivity and binding cooperativity of braf inhibitors
Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J. (2025) · eLife · doi:10.7554/elife.95334.4 · Cited by 7
Self-citationNeurofibromatosis as a gateway to better treatment for a variety of malignancies
Bakker, A. C., Rosa, S. L., Sherman, L. S., Knight, P. B., Lee, H.-R., Pancza, P., & Nievo, M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.004 · Cited by 10
Twist1 sustains the apoptosis resistance in eosinophils in nasal mucosa of allergic rhinitis
Shao, J., Luo, X., Mo, L., Yang, G., Liu, Z., Liu, J., Liu, Z., Liu, D., & Yang, P. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108828 · Cited by 9
microRNA-196b alleviates lipopolysaccharide-induced inflammatory injury by targeting NRAS
Chen, N., Ma, B., Guo, S., Yin, B., Zhang, J., & Deng, G. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.03.122 · Cited by 9
Dyshlovoy, S. A., Busenbender, T., Hauschild, J., Girich, E. V., Kriegs, M., Hoffer, K., Graefen, M., Yurchenko, A. N., Bokemeyer, C., & Amsberg, G. V. (2022) · Marine Drugs · doi:10.3390/md20100597 · Cited by 9
KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
Lian, S., Tan, L.-X., Liu, X.-Z., Yang, L., Li, N.-N., Feng, Q., Wang, P., Wang, Y., Qiao, D., Zhou, L., et al. (2023) · Medicine · doi:10.1097/md.0000000000033115 · Cited by 10
Yu, A., Nguyen, D. H., Nguyen, T. J., & Wang, Z. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105188 · Cited by 13
Advances in research on autophagy mechanisms in resistance to endometrial cancer treatment
Ji, J., Cheng, X., Du, R., Xie, Y., & Zhang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1364070 · Cited by 12
Wen, S., Xiao, H., Yang, P., Zhang, Y., Bu, F., Wu, Y., Sun, Q., Wang, G., & Ouyang, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02392 · Cited by 10
Protein tyrosine phosphatases: emerging role in cancer therapy resistance
Zhao, M., Shuai, W., Su, Z., Xu, P., Wang, A., Sun, Q., & Wang, G. (2024) · 癌症:英文版 · doi:10.1002/cac2.12548 · Cited by 10
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Liu, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00615-9 · Cited by 10
Shrestha, G., MacNeil, S. M., McQuerry, J. A., Jenkins, D. F., Sharma, S., & Bild, A. H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.012 · Cited by 10
Ouyang, W., Guo, P., Fang, H., & Frucht, D. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.805648 · Cited by 9
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27388 · Cited by 9
Gastl, B., Klotz‐Noack, K., Klinger, B., Ispasanie, S., Salib, K. H. F., Zuber, J. A., Mamlouk, S., Bublitz, N., Blüthgen, N., Horst, D. A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2704-9 · Cited by 11
Lu, S., & Zhang, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12324-8 · Cited by 9
Enhanced anti-hepatoma effect of a novel curcumin analog C086 via solid dispersion technology
Deng, Y., Chen, C., Xiao, Z., Huang, X., & Xu, J. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1785051 · Cited by 9
Zhang, B., Wu, D., Hu, L., Cha, X., Liu, Y., Li, J., Xie, B., Li, B., & Zheng, L. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118993 · Cited by 9
Liu, H., Li, J., Jiang, C., Yuan, T., & Ma, H. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101737 · Cited by 8
Li, P., Cao, S., Huang, Y., Zhang, Y., Liu, J., Cai, X., Zhou, L., Li, J., Jiang, Z., Ding, L., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00580-3 · Cited by 9
Phospholipase D1 promotes cervical cancer progression by activating the RAS pathway
Song, M., Meng, Q., Jiang, X., Liu, J., Xiao, M., Zhang, Z., Wang, J., & Bai, H. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17439 · Cited by 9
Gui, L., Zhu, Y., Li, X., He, X., Ma, T., Cai, Y., & Liu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178682 · Cited by 11
Optogenetic actuator/ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M.-A., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2021) · doi:10.1101/2021.07.27.453955 · Cited by 9
Computational analysis of natural product B-Raf inhibitors
Chettri, S., Sasmal, P., Adon, T., Kumar, B. S., Kumar, B. R. P., & Raghavendra, N. M. (2022) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2022.108340 · Cited by 8
Sinularin stabilizes FOXO3 protein to trigger prostate cancer cell intrinsic apoptosis
Meng, X., Wang, K., Ye, S., Chen, J., Chen, Z.-Y., Zhang, Z., Yin, W.-Q., Jia, X.-L., Li, Y., Yu, R., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116011 · Cited by 9
Lei, H., Xiang, T., Zhu, H., & Hu, X. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903129 · Cited by 12
Sirek, T., Król-Jatręga, K., Borawski, P., Zmarzły, N., Boroń, D., Ossowski, P., Nowotny-Czupryna, O., Boroń, K., Janiszewska-Bil, D., Mitka-Krysiak, E., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1515387 · Cited by 11
Role of ERK1/2 and p38 Protein Kinases in Tumors: Biological Insights and Clinical Implications
Emelyanova, A., Modestov, A., Buzdin, A. A., & Poddubskaya, E. V. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl31317 · Cited by 12
Molavand, M., Majidinia, M., & Yousefi, B. (2025) · IUBMB Life · doi:10.1002/iub.70074 · Cited by 10
Labenski, M., Bateman, L. A., Voortman, L., Giammo, G., Cantin, S. M., Qiao, L., & Corin, A. F. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00422 · Cited by 8
A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer
Liu, W., Gajendran, B., Sample, K. M., Wang, C., Hu, A., Chen, B., Li, Y., Zacksenhaus, E., & Ben‐David, Y. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00471-4 · Cited by 9
Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10
Yang, J., Hou, C., Wang, H., Perez, E. A., Do-Umehara, H. C., Dong, H., Arunagiri, V., Tong, F., Scoyk, M. M. V., Cho, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216025 · Cited by 8
Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression
Xie, S., Xu, C., Wu, C., Lou, Y., Duan, J., Sang, R., Lou, Z., Hou, J., Ge, W., Xi, Y., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04708-9 · Cited by 8
Current and future perspectives on the regulation and functions of miR-545 in cancer development
Shen, J., Su, X., Wang, Q., Ke, Y., Zheng, T., Mao, Y., Wang, Z., Dong, J., & Duan, S. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.09.001 · Cited by 8
Wolfe, A. R., Feng, H., Zuniga, O., Rodrigues, H., Eldridge, D. E., Yang, L., Shen, C., & Williams, T. M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2024.216873 · Cited by 9
PESSA: A web tool for pathway enrichment score-based survival analysis in cancer
Yang, H. Y., Shi, Y., Lin, A., Qi, C., Liu, Z., Cheng, Q., Miao, K., Zhang, J., & Luo, P. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012024 · Cited by 9
Shu, J., Zhang, M., Dong, X., Long, J., Li, Y., Tan, P., He, T., Giovannucci, E. L., Zhang, X., Zhou, Z., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae116 · Cited by 8
Designed dualsteric modulators: A novel route for drug discovery
Li, N., Zheng, G., Fu, L., Liu, N., Chen, T., & Lu, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104141 · Cited by 9
MEK inhibitors in oncology: a patent review and update (2016 – present)
Suryavanshi, A., Vandana, Shukla, Y. K., Kumar, V., Gupta, P., Asati, V., Mahapatra, D. K., Keservani, R. K., Jain, S. K., & Bharti, S. K. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2403634 · Cited by 17
Boraei, A. T. A., Nafie, M. S., Barakat, A., Tanaka, T., Kawano, K., Tojo, T., Aoki, S., & Sarhan, A. A. M. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108154 · Cited by 9
Kim, S., Kim, I. H., Jang, K. W., Kim, M. H., Sohn, J., Yun, M. R., Kang, H. N., Kang, C. W., Kim, H. R., Lim, S. M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0375 · Cited by 9
RetractedWang, Q., Satomi, K., Oh, J. E., Hutter, B., Brors, B., Diessl, N., Liu, H., Wolf, S., Wiestler, O. D., Kleihues, P., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.05.024 · Cited by 12
Tsubaki, M. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00142 · Cited by 8
KRAS as Potential Target in Colorectal Cancer Therapy
Eng, S.-K., Loh, T. H. T., Goh, B. H., & Lee, W.-L. (2019) · Springer eBooks · doi:10.1007/978-981-13-7154-7_12 · Cited by 10
Giannopoulou, A. F., Velentzas, A. D., Anagnostopoulos, A. K., Agalou, A., Papandreou, N. C., Katarachia, S. A., Koumoundourou, D. G., Konstantakou, E. G., Pantazopoulou, V. I., Delis, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13092024 · Cited by 8
Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
Catalano, A., Adlesic, M., Kaltenbacher, T., Klar, R. F. U., Albers, J., Seidel, P., Brandt, L. P., Hejhal, T., Busenhart, P., Röhner, N., et al. (2021) · Cancers · doi:10.3390/cancers13081852 · Cited by 11
Assessment of PI3K/AKT and MAPK/ERK pathways activation in oral lymphatic malformations
Gomes, I. P., Guimarães, L. M., Pereira, T. D. S. F., Braga, N. P., Martins, M. D., Gomez, R. S., & Gomes, C. C. (2021) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2021.08.018 · Cited by 10
ZC3H15 Correlates with a Poor Prognosis and Tumor Progression in Melanoma
Li, Q., Hou, J., Guo, C., Zhang, Y., Liu, L., Hu, H., Shi, S., Ji, Y., Guo, L., Shi, Y., et al. (2021) · BioMed Research International · doi:10.1155/2021/8305299 · Cited by 9
RetractedYoshikawa, H., Nishino, K., & Kosako, H. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104543 · Cited by 10
A potent tumor-selective ERK pathway inactivator with high therapeutic index
Zuo, Z., Liu, J., Sun, Z., Silverstein, R., Zou, M., Finkel, T., Bugge, T. H., Leppla, S. H., & Liu, S. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac104 · Cited by 8
Elnaggar, M., Agte, S., Restrepo, P., Ram, M., Melnekoff, D. T., Adamopoulos, C., Stevens, M. M., Kappes, K., Leshchenko, V. V., Verina, D., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01330-3 · Cited by 10
Self-citationVairy, S., Jouan, L., Bilodeau, M., Dormoy-Raclet, V., Gendron, P., Couture, F., Léveillé, F., Tihy, F., Lemyre, E., Soglio, D. B. D., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00007 · Cited by 8
Long Non-coding RNA AK025387 Promotes Cell Migration and Invasion of Gastric Cancer
Sun, Y., Zhang, H., Ma, R., Zhang, G., Tian, Y., Liu, L., Liu, L., & Gao, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00633 · Cited by 8
Cursons, J., Angel, C. E., Hurley, D., Print, C. G., Dunbar, P. R., Jacobs, M. D., & Crampin, E. J. (2015) · GigaScience · doi:10.1186/s13742-015-0102-5 · Cited by 7
Zhang, H., & Luo, J. (2016) · Small GTPases · doi:10.1080/21541248.2016.1161698 · Cited by 9
Live-cell target engagement of allosteric MEKi on MEK–RAF/KSR–14-3-3 complexes
Marsiglia, W. M., Chow, A., Khan, Z. M., Liu, H., & Dar, A. C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01454-8 · Cited by 9
Khan, A., Zahid, M., Farrukh, F., Abdelsalam, S. S., Mohammad, A., Al‐Zoubi, R. M., Shkoor, M., Hssain, A. A., Wei, D., & Agouni, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112833 · Cited by 8
Lu, S., Hou, B.-L., Wang, T., Ma, K., Huang, A., Wu, X. Z., Liang, Y.-N., & Wang, Z. (2025) · ACS Omega · doi:10.1021/acsomega.4c11189 · Cited by 8
Huang, Z., Fang, J., Li, L., Cai, N., Chen, S., He, G., Cao, Y., Wu, G., Wang, Y., Li, W., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03577-7 · Cited by 7
Salinas, A. J., Tevdorashvili, K., Grim, J., Morales, A., Chakhrakia, A., & Lee, Y. K. (2026) · Nature Communications · doi:10.1038/s41467-026-69437-6 · Cited by 6
Misshapen Disruption Cooperates with RasV12 to Drive Tumorigenesis
Kong, D., Lu, J., Li, X., Zhao, S., Xu, W., Fang, J., Wang, X., & Ma, X. (2021) · Cells · doi:10.3390/cells10040894 · Cited by 8
Cao, H., Wang, Z., Wang, Y., Ye, L., Li, R., Xue, Y., Li, K., Di, T., Li, T., Fan, Z., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5443 · Cited by 8
Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
Ding, Y., Liu, C., Wu, Y., & Fu, F. (2023) · Biomedical Technology · doi:10.1016/j.bmt.2023.03.003 · Cited by 7
Tubita, A., Menconi, A., Lombardi, Z., Tusa, I., Esparís-Ogando, A., Pandiella, A., Gamberi, T., Stecca, B. A., & Rovida, E. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.03.015 · Cited by 11
Wu, X., Gong, L., Li, B., Bai, J., Li, C., Zhang, Y., & Hai-bo, Z. H. U. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14749 · Cited by 7
Dong, L., Choi, H., Budhu, S., Schulze, I., Verma, S., Mangarin, L. M. B., Navarro, V. E., Mehanna, N., Khan, J. F., Venkatesh, D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0729 · Cited by 7
Wang, H., Chen, Y., Yang, Y., Song, R., Gu, S., Cao, X., Zhang, L., Yang, Y., Hou, T., Qi, X., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07427-0 · Cited by 9
Yadav, V., Kashif, M., Kamali, Z., Gourinath, S., & Subbarao, N. (2025) · Molecular Informatics · doi:10.1002/minf.202400372 · Cited by 7
Previtali, V., Trujillo, C., Amet, R., Zisterer, D. M., & Rozas, I. (2018) · MedChemComm · doi:10.1039/c8md00089a · Cited by 7
Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication
Bell, T. M., Espina, V. A., Lundberg, L., Pinkham, C., Brahms, A., Carey, B. D., Lin, S., Dahal, B., Lehman, C. W., de la Fuente, C., et al. (2018) · Viruses · doi:10.3390/v10040191 · Cited by 7
RASpecting the oncogene: New pathways to therapeutic advances
Stout, M. C., & Campbell, P. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.022 · Cited by 7
Gautam, V., Chong, W. L., Chin, S. P., Zain, S. M., Rahman, N. A., Vao‐soongnern, V., & Lee, V. S. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.10.157 · Cited by 10
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 7
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
Cândido, M. F., Medeiros, M., Veronez, L. C., Bastos, D., Oliveira, K. L., Pezuk, J. A., Valera, E. T., & Brassesco, M. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020664 · Cited by 8
Up-front polytherapy for ALK-positive lung cancer
Zhou, B., & Cox, A. D. (2015) · Nature Medicine · doi:10.1038/nm.3942 · Cited by 7
Tian, P., Zhu, Y., Zhang, C., Guo, X., Zhang, P., & Xue, H. (2018) · BMC Cancer · doi:10.1186/s12885-018-5199-3 · Cited by 8
RetractedYoshida, T., Suganuma, N., Sato, S., Toda, S., Nakayama, H., Masudo, K., Okubo, Y., Hayashi, H., Yokose, T., Koshikawa, N., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.043 · Cited by 10
RACK1 modulates polyglutamine-induced neurodegeneration by promoting ERK degradation in Drosophila
Xie, J., Han, Y., & Wang, T. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009558 · Cited by 8
Rowdo, F. P. M., Barón, A., von Euw, E. M., & Mordoh, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5363 · Cited by 7
Zhang, B., Zhang, H., Wang, Z., Cao, H., Zhang, N., Dai, Z., Liang, X., Peng, Y., Wen, J., Zhang, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14500 · Cited by 6
Artschwager, R., Kalidindi, T. M., Johnson, D. S., Brennan, C., Samuels, Z. V., Lito, P., & Pillarsetty, N. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00425 · Cited by 6
Wan, X., Yap, J., Chen, J., Li, Y., Faruk, R., Boon, N. T. C., Ma, Y., Lim, Y., Jubri, K. B., Hu, J., et al. (2025) · Theranostics · doi:10.7150/thno.103958 · Cited by 6
Zhang, S., Li, J., Jin, Q., Zhu, S., Yan, H., Wang, Y., Song, Z., & Liu, L. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.064300 · Cited by 6
Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., LaMorte, J. P., Gambhir, V., Beckley, Z., Linke, A. J., Wilkerson, M. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adx5186 · Cited by 7
Ushijima, T., & Yoshino, T. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2867 · Cited by 6
Vargas-Ibarra, D., Velez-Vasquez, M., & Bermudez‐Muñoz, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97061 · Cited by 10
Zeppa, L., Aguzzi, C., Versari, G., Luongo, M., Morelli, M. B., Maggi, F., Amantini, C., Santoni, G., Marinelli, O., & Nabissi, M. (2022) · Pharmaceuticals · doi:10.3390/ph15040466 · Cited by 6
Xiao, M., Pang, C., Xiang, S., Zhao, Y., Wu, X., Li, M., Du, F., Chen, Y., Wang, F., Wen, Q., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-26776-w · Cited by 7
Luna, A. J., Young, J. M., Sterk, R. T., Bondu, V., Schultz, F. A., Kusewitt, D. F., Kang, H., & Ozbun, M. A. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105667 · Cited by 8
Chiang, C.-Y., Zhang, M., Huang, J., Zeng, J., Chen, C., Pan, D., Yang, H., Zhang, T., Yang, M., Han, Q., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01164-w · Cited by 6
Hsu, S., Tsai, Y.-L., Wang, Y., Shen, C., Hung, Y., Chen, L., & Hung, W. (2024) · Advanced Science · doi:10.1002/advs.202304820 · Cited by 9
Grützner, C., Tan, Y. P., Müller, P., Schlee-Guimaraes, T. M., Jentzsch, M., Schmid-Burgk, J. L., Renn, M., Behrendt, R., & Hartmann, G. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102283 · Cited by 8
N-cap helix nucleation: methods and their applications
Wang, D., Qin, X., Zhao, H., & Li, Z. (2017) · Science China Chemistry · doi:10.1007/s11426-016-9033-y · Cited by 8
Role of ESR Pathway Genes in Breast Cancer: A Review
Kumar, D., Myers, M. R., Homsi, U. A., & Ilyin, V. (2018) · Advances in Breast Cancer Research · doi:10.4236/abcr.2018.72010 · Cited by 7
Zou, Q., Ma, S., Tian, X., & Cai, Q. (2022) · Blood Science · doi:10.1097/bs9.0000000000000114 · Cited by 7
Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells.
Fernandes, G. M. D. M., Serafim, V., Galbiatti, A. L. S., Ferreira, L. A. M., Castanhole-Nunes, M. M. U., Kawasaki‐Oyama, R. S., Maníglia, J. V., Pavarino, É. C., & Goloni‐Bertollo, E. M. (2022) · PubMed · Cited by 6
Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
Shen, M., Su, Y., Song, S., Liu, D., Liu, Z., Chen, D., Pan, Y., Zhang, L., & Xu, X. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.3.8 · Cited by 6
Batsi, Y., Αντωνοπούλου, Γ., Fotopoulou, T., Koumaki, K., Kritsi, E., Potamitis, C., Goulielmaki, M., Skarmalioraki, S., Papalouka, C., Poulou‐Sidiropoulou, E., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202300322 · Cited by 6
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.